ESSA Pharma Securities Class Action

Levi & Korsinsky, LLP has initiated a class action securities lawsuit against ESSA Pharma, Inc. (NASDAQ: EPIX) on behalf of investors who suffered losses between December 12, 2023, and October 31, 2024. The lawsuit alleges that ESSA Pharma made false and misleading statements and concealed information regarding the efficacy of its drug, masofaniten, in combination with enzalutamide for treating prostate cancer. Specifically, the complaint claims that the combination had no clear efficacy benefit over enzalutamide alone, was less effective than investors were led to believe, and that the M-E Combination Study was unlikely to meet its primary endpoint. Consequently, ESSA Pharma is accused of overstating masofaniten's clinical, regulatory, and commercial prospects. Investors have until March 25, 2025, to request to be appointed as lead plaintiff.